Fig. 7

OTP-BTFPTU liposomes exhibit anti-drug resistance and can regulate the tumor immune microenvironment. (A) Cell viability of HOS-DDPR (cisplatin-resistant osteosarcoma cell line), 97 H-SR (sorafenib-resistant hepatoma cell line), MDA-MB-231 and BT549 (triple negative breast cancer cell lines) cells with OTP-BTFPTU liposomes treatment for 24 h using Cell Counting Kit-8 assay. (B) Schematic illustration of obtaining conditional medium (CM). (C) The mRNA level of iNOS, IL-1β, IL-10 and ARG1 in BMMs following M1 or M2 macrophage induction in the presence of 50% control or OTP-BTFPTU liposomes CM. (D) DAPI (blue), F4/80 (green) and CD86 (red) immunofluorescence of tumor sections from mice treated with or without OTP-BTFPTU liposomes. Scale bars, 50 μm. (E) Quantification of M1 macrophage (F4/80⁺＆CD86⁺) ratio. (F) DAPI (blue), F4/80 (green) and CD206 (red) immunofluorescence of tumor sections from mice treated with or without OTP-BTFPTU liposomes. Scale bars, 50 μm. (G) Quantification of M2 macrophage (F4/80⁺＆CD206⁺) ratio. The data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 for a comparison with the control group or as indicated